Neurological manifestations of post-covid syndrome


Дәйексөз келтіру

Толық мәтін

Ашық рұқсат Ашық рұқсат
Рұқсат жабық Рұқсат берілді
Рұқсат жабық Рұқсат ақылы немесе тек жазылушылар үшін

Аннотация

Post-covid syndrome is one of the new problems that healthcare is faced during the COVID-19 pandemic. According to clinical studies results, up to one third of SARS-CoV-2 infected patients develop neurological symptoms which could last for months after regress of respiratory syndrome. The most common neurological disturbances associated with COVID-19 are fatigue, asthenia, cognitive impairment, smell and taste decrease, cerebral vascular disease, peripheral neuropathy, pain etc. Clinical symptoms of post-covid syndrome significantly affects the quality of life and working capacity of many patients. Nowadays therapeutic strategies of post-covid syndrome treatment are empirical and are based on possible pathogenesis of neurological complications. Prevention of cerebral vascular events and neurometabolic treatment of cognitive and asthenic disorders should play an important role in management of COVID-19 patients. Pentoxifylline could be considered as coadjuvant measure in treatment of post-covid neurological symptoms because of its multimodal effects.

Толық мәтін

Рұқсат жабық

Авторлар туралы

Vladimir Zakharov

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

Email: dariagromova87@gmail.com
MD, professor, professor of the Department of nervous diseases and neurosurgery

Daria Gromova

I.M. Sechenov First Moscow State Medical University of the Ministry of Healthcare of Russia (Sechenov University)

neurologist, senior laboratory assistant at the Department of nervous diseases and neurosurgery

Әдебиет тізімі

  1. Mao L., Jin H., Wang M. et al. Neurologic manifestations of hospitalized patients with coronavirus disease 2019 in Wuhan, China. JAMA Neurol. 2020; 77(6): 683-90. https://doi.org/10.1001/jamaneurol.2020.1127.
  2. Lu Y., Li X., Geng D. et al. Cerebral micro-structural changes in COVID-19 patients - an MRI-based 3-month follow-up study. EClinicalMedicine. 2020; 25: 100484. https://doi.org/10.1016/j.eclinm.2020.100484.
  3. Miners S., Kehoe P.G., Love S. Cognitive impact of COVID-19: looking beyond the short term. Alzheimers Res Ther. 2020; 12(1): 170. https://doi.org/10.1186/s13195-020-00744-w.
  4. Tsai S.T., Lu M.K., San S., Tsai C.H. The neurologic manifestations of coronavirus disease 2019 pandemic: A systemic review. Front Neurol. 2020; 11: 498. https://doi.org/10.3389/fneur.2020.00498.
  5. Белопасов В.В., Яшу Я., Самойлова Е.М., Баклаушев В.П. Поражение нервной системы при TOVID-19. Клиническая практика. 2020; 2: 60-80.
  6. Преображенская И.С. Неврологические проявления COVID-19. Эффективная фармакотерапия. 2020; 23: 50-55
  7. Хасанова Д.Р., Житкова Ю.В., Васкаева Г.Р. Постковидный синдром: обзор знаний о патогенезе, нейропсихиатрических проявлениях и перспективах лечения. Неврология, нейропсихиатрия, психосоматика. 2021; 3: 93-98
  8. Айнабекова Б.А., Баев В.В., Васильев С.А. с соавт. Рекомендации по ведению больных с коронавирусной инфекцией COVID-19 в острой фазе и при постковидном синдроме в амбулаторных условиях. Под редакцией профессора Воробьева П.А. Москва, 2021. Проблемы стандартизации в здравоохранении. 2021; 7-8: 3-96
  9. Davido B., Seang S., Tubiana R., de Truchis P. Post-COVID-19 chronic symptoms: a post-infectious entity? Clin Microbiol Infec. 2020; 26(11): 1448-49. https://dx.doi.org/10.1016/j.cmi.2020.07.028.
  10. Office for National Statistics. Prevalence of ongoing symptoms following coronavirus (COVID-19) infection in the UK: 1 April 2021. URL: https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/bulletins/prevalenceofongoingsymptomsfollowingcoronaviruscovid19infectionintheuk/1april2021 (date of access - 11.01.2022).
  11. National Health Service (NHS). Long-term effects of coronavirus (long COVID). URL: https://www.nhs.uk/conditions/coronavirus-covid-19/long-term-effects-of-coronavirus-long-covid (date of access - 11.01.2022).
  12. Taquet M., Geddes J.R., Husain M. et al. 6-month neurological and psychiatric outcomes in 236 379 survivors of COVID-19: a retrospective cohort study using electronic health records. Lancet Psychiatry. 2021; 8(5): 416-27. https://dx.doi.org/10.1016/S2215-0366(21)00084-5.
  13. Vanichkachorn G., Newcomb R., Cowl C.T. et al. Post-COVID-19 syndrome (long haul syndrome): Description of a multidisciplinary clinic at Mayo clinic and characteristics of the initial patient cohort. Mayo Clin Proc. 2021; 96(7): 1782-91. https://dx.doi.org/10.1016/j.mayocp.2021.04.024.
  14. De Erausquin G.A., Snyder H., Carrillo M. et al. The chronic neuropsychiatric sequelae of COVID-19: The need for a prospective study of viral impact on brain functioning. Alzheimer's Dement. 2021; 17(6): 1056-65. https://dx.doi.org/10.1002/alz.12255.
  15. Chow J.H., Khanna A.K., Kethireddy S. et al. Aspirin use is associated with decreased mechanical ventilation, intensive care unit admission, and in-hospital mortality in hospitalized patients with coronavirus disease 2019. Anesth Analg. 2021; 132(4): 930-41. https://dx.doi.org/10.1213/ANE.0000000000005292.
  16. Liu Q., Huang N., Li A. et al. Effect of low-dose aspirin on mortality and viral duration of the hospitalized adults with COVID-19. Medicine (Baltimore). 2021; 100(6): e24544. https://dx.doi.org/10.1097/MD.0000000000024544.
  17. Sisinni A., Rossi L., Battista A. et al. Pre-admission acetylsalicylic acid therapy and impact on in-hospital outcome in COVID-19 patients: The ASA-CARE study.Int J Cardiol. 2021; 344: 240-45. https://dx.doi.org/10.1016/j.ijcard.2021.09.058. Epub ahead of print.
  18. Abdelwahab H.W., Shaltout S.W., Sayed Ahmed H.A. et al. Acetylsalicylic acid compared with enoxaparin for the prevention of thrombosis and mechanical ventilation in COVID-19 patients: A retrospective cohort study. Clin Drug Investig. 2021; 41(8): 723-32. https://dx.doi.org/10.1007/s40261-021-01061-2.
  19. Osborne T.F., Veigulis Z.P., Arreola D.M. et al. Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration. PLoS One. 2021; 16(2): e0246825. https://dx.doi.org/10.1371/journal.pone.0246825.
  20. Meizlish M.L., Goshua G., Liu Y. et al.Intermediate-dose anticoagulation, aspirin, and in-hospital mortality in COVID-19: A propensity score-matched analysis. Am J Hematol. 2021; 96(4): 471-79. https://dx.doi.org/10.1002/ajh.26102.
  21. Haji Aghajani M., Moradi O., Amini H. et al. Decreased in-hospital mortality associated with aspirin administration in hospitalized patients due to severe COVID-19. J Med Virol. 2021; 93(9): 5390-95. https://dx.doi.org/10.1002/jmv.27053.
  22. Sahai A., Bhandari R., Godwin M. et al. Effect of aspirin on short-term outcomes in hospitalized patients with COVID-19. Vasc Med. 2021; 26(6): 626-32. https://dx.doi.org/10.1177/1358863X211012754.
  23. Yuan S., Chen P., Li H. et al. Mortality and pre-hospitalization use of low-dose aspirin in COVID-19 patients with coronary artery disease. J Cell Mol Med. 2021; 25(2): 1263-73. https://dx.doi.org/10.1111/jcmm.16198.
  24. Pan D., Ip A., Zhan S. et al. Pre-hospital antiplatelet medication use on COVID-19 disease severity. Heart Lung. 2021; 50(5): 618-21. https://dx.doi.org/10.1016/j.hrtlng.2021.04.010.
  25. Connors J.M., Brooks M.M., Sciurba F.C. et al.; ACTIV-4B Investigators. Effect of antithrombotic therapy on clinical outcomes in outpatients with clinically stable symptomatic covid-19: the ACTIV-4B randomized clinical trial. JAMA. 2021; 326(17): 1703-12. https://dx.doi.org/10.1001/jama.2021.17272.
  26. European pentoxifylline multi-infarct dementia study. Eur Neurol. 1996; 36(5): 315-21. https://dx.doi.org/10.1159/000117279.
  27. Sha M., Callahan C. The efficacy of pentoxifylline in the treatment of vascular dementia: a systematic review. Alzheimer Dis Assoc Disord. 2003; 17(1): 46-54. https://dx.doi.org/10.1097/00002093-200301000-00006.
  28. Колесников, А.Н., Гридасова, Е.И., Кучеренко, Е.А. с соавт. Целесообразность применения пентоксифиллина при COVID-19 (литературный обзор). Университетская клиника. 2021; 1: 88-94. [Kolesnikov A.N., Gridasova E.I., Kucherenko E.A. et al. Feasibility of using pentoxyphylline in COVID-19 (literature review). Universitetskaya klinika = University Hospital. 2021; 1: 88-94 (In Russ.)]. https://dx.doi.org/10.26435/UC.V0I1(38).626.
  29. Dhameliya H.A., Thakkar V.R., Trivedi G.N. et al. Pentoxifylline: An immunomodulatory drug for the treatment of COVID-19. J Pure Appl Microbiol. 2020; 14(suppl 1): 861-67. https://dx.doi.org/10.22207/JPAM.14.SPL1.23.
  30. Hendry B.M., Stafford N., Arnold A.D. et al. Hypothesis: Pentoxifylline is a potential cytokine modulator therapeutic in COVID-19 patients. Pharmacol Res Perspect. 2020; 8(4): e00631. https://dx.doi.org/10.1002/prp2.631.
  31. Seirafianpour F., Mozafarpoor S., Fattahi N. et al. Treatment of COVID-19 with pentoxifylline: Could it be a potential adjuvant therapy? Dermatol Ther. 2020; 33(4): e13733. https://dx.doi.org/10.1111/dth.13733.
  32. Monji F., Al-Mahmood Siddiquee A., Hashemian F. Can pentoxifylline and similar xanthine derivatives find a niche in COVID-19 therapeutic strategies? A ray of hope in the midst of the pandemic. Eur J Pharmacol. 2020; 887: 173561. https://dx.doi.org/10.1016/j.ejphar.2020.173561
  33. Rainsford K.D. Influenza («Bird Flu»), inflammation and anti-inflammatory/ analgesic drugs. Inflammopharmacology. 2006; 14(1-2): 2-9. https://dx.doi.org/10.1007/s10787-006-0002-5.
  34. Wall G.C., Smith H.L., Trump M.W. et al. Pentoxifylline or theophylline use in hospitalized COVID-19 patients requiring oxygen support. Clin Respir J. 2021; 15(7): 843-46. https://dx.doi.org/10.1111/crj.13363.

Қосымша файлдар

Қосымша файлдар
Әрекет
1. JATS XML
Жүктеу

© Bionika Media, 2022

Осы сайт cookie-файлдарды пайдаланады

Біздің сайтты пайдалануды жалғастыра отырып, сіз сайттың дұрыс жұмыс істеуін қамтамасыз ететін cookie файлдарын өңдеуге келісім бересіз.< / br>< / br>cookie файлдары туралы< / a>